We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Spotlight Consultations

Status: Expired

Jan 14th 2021 - Feb 13th 2021

Spotlight Consultations aims to diagnose diseases based on evidence-based questionnaires. The company's Algorithmic Questionnaire (AQ) strives to be a simple 3-5 minute questionnaire, dynamically responsive with each question linked to an actionable care pathway. The company estimates that 10% of global health expenditure per annum is spent on diabetes, which is predicted to rise to $825 billion by 2030. Indirect costs from premature death, disability, and diabetes-related health complications add an additional 35% more to this number. Spotlight intends for its AQ to help reduce expenditure and healthcare burden while improving the quality of care and health outcomes. The company will use the investment to support early revenue generation, team expansion and stimulate Research and Development (R&D) tools to cover more diseases like CVD, IBD, chronic pain, and cancers.

read more read less

Spotlight Consultations Rating Review

Pitch rating powered by CROWDRATING

Rated on 10/02/2021

Pitch Rated

54%

Insufficient Data

Management

87%

Product

76%

Investment

UNRATED*

* Section unrated owing to insufficient or incomplete information available at the time of rating.

Log in to view amount pledged

    Log in to view target

    £4,997,951
    pre-money valuation

    2.44%
    equity available

    104
    investors

    £670
    pledge per investor

    12951595
    company number

    Active
    company status

    14/10/2020
    incorporated 4 years

    £2.50
    share price

    Previous Funding rounds
    22 Apr 24 Crowdcube £69,682 / 56% 54.33%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 87%

Skills 91%
The Spotlight Consultations management team includes skilled professionals with management, diabetes, technology, sales, and marketing expertise. It consists of an experienced Founder/Chief Executive Officer, Co-founder/Chief Science Officer, and Co-Founder/Chief Medical Officer. The Founder/Chief Executive Officer is competent in business strategy, project management, strategic planning, and business development. He also has prior experience working at the same stage of business growth and has also invented and patented 'Spotlight Digital Health Tool' along with Co-founder/CSO. The Chief Science Officer Clinical Research is a doctorate in Health Psychology and specialises in clinical research, psychology, research design, quantitative research, and clinical psychology. She has been awarded the first-ever FDA MDDT qualification for the INSPIRE psychosocial measures and published over 220 peer-reviewed articles in high-quality medical journals worldwide, including the New England Journal of Medicine and The Lancet. The Chief Medical Officer is an award-winning Physician/Researcher who has expertise in medicine, pharmaceuticals, pain management, medical devices, and healthcare information technology. He won the Gold Clinical Excellence award by the NHS in 2006 and has 88 publications on diabetes and healthcare. He also won the Champion in Health Care Award in 2020 and the Leadership Award for Diabetes Technology Society in 2017.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £4,997,951
    pre-money valuation

    2.44%
    equity available

    104
    investors

    £670
    pledge per investor

    12951595
    company number

    Active
    company status

    14/10/2020
    incorporated 4 years

    £2.50
    share price

    Previous Funding rounds
    22 Apr 24 Crowdcube £69,682 / 56% 54.33%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph